ReviewSeminars in immunopathology2015
Exploiting fungal cell wall components in vaccines.
Review in Seminars in immunopathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 68 citations in OpenAlex.
- Oral yeast-displayed SARS-CoV-2 spike protein vaccine enhanced by trimerization and flagellin peptide.Scientific reports · 2026Article
- Mannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1Infection and immunity · 2026Article
- Associations and interactions between prokaryotes and other gut biota in non-human primates.Primates; journal of primatology · 2026Review
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Exploring the structural basis and functional immunodynamics of immunoglobulin M in host defense against fungal pathogens.Frontiers in immunology · 2025Review
- Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.Journal of fungi (Basel, Switzerland) · 2024Review
- Chitosan-Deficient Cryptococcus as Whole-Cell Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Understanding yeast shells: structure, properties and applications.ADMET & DMPK · 2024Review
- Gene Family Expansion during the Adaptation ofJournal of fungi (Basel, Switzerland) · 2023Article
- Immunization with a heat-killed prm1 deletion strain protects the host fromEmerging microbes & infections · 2023Article
- Optimal Extraction and Deproteinization Method for Mannoprotein Purification from Kluyveromyces marxianus.Iranian biomedical journal · 2023Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- They shall not grow mold: Soldiers of innate and adaptive immunity to fungi.Seminars in immunology · 2023Review
- Article
- Transcriptional Network inJournal of fungi (Basel, Switzerland) · 2022Article
- Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus onFrontiers in medicine · 2022Review
- Role of Protein Glycosylation in Interactions of Medically Relevant Fungi with the Host.Journal of fungi (Basel, Switzerland) · 2021Review
- Vaccines for human fungal diseases: close but still a long way to go.NPJ vaccines · 2021Review
- Harnessing antifungal immunity in pursuit of a Staphylococcus aureus vaccine strategy.PLoS pathogens · 2020Article
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Innate recognition of fungi leads to strong adaptive immunity. Investigators are trying to exploit this observation in vaccine development by combining antigens with evolutionarily conserved fungal cell wall carbohydrates to induce protective responses. Best studied is β-1,3-glucan, a glycan that activates complement and is recognized by dectin-1. Administration of antigens in association with β-1,3-glucan, either by direct conjugation or complexed in glucan particles, results in robust humoral and cellular immune responses. While the host has a host of mannose receptors, responses to fungal mannoproteins generally are amplified if cells are cooperatively stimulated with an additional danger signal such as a toll-like receptor agonist. Chitosan, a polycationic homopolymer of glucosamine manufactured by the deacetylation of chitin, is being studied as an adjuvant in DNA and protein-based vaccines. It appears particularly promising in mucosal vaccines. Finally, universal and organism-specific fungal vaccines have been formulated by conjugating fungal cell wall glycans to carrier proteins. A major challenge will be to advance these experimental findings so that at risk patients can be protected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.